Highlights of weekly biotech stock moves

Amsterdam Molecular Therapeutics Holding N.V. (Euronext:AMT) was off €0.02 to €0.98 on Friday after asking EMA to reexamine an MAA for Glybera to treat lipoprotein lipase (LPL) deficiency. Last month, the agency's CHMP recommended against approval. The biotech expects the reexamination to be completed by year end. Amsterdam Molecular was up €0.02 last week (see "Proving Chylomicrons Matter," A14).

Gentium S.p.A. (NASDAQ:GENT) lost $0.26 to $9.73 last week after submitting an NDA to FDA for defibrotide to treat hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem-cell transplantation therapy. Sigma-Tau S.p.A. has rights to develop and commercialize the compound. in the Americas An MAA is under accelerated EMA review...